查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1833557

2032 年神经系统疾病数位生物标记市场预测：按类型、适应症、临床用途、最终用户和地区进行的全球分析

Digital Biomarkers for Neurological Conditions Market Forecasts to 2032 - Global Analysis By Type (Wearable Devices, Mobile Applications, Sensors and Software Platforms), Indication, Clinical Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球神经系统疾病数位生物标记市场预计在 2025 年达到 8.949 亿美元，到 2032 年将达到 46.386 亿美元，预测期内的复合年增长率为 26.5%。

神经系统疾病的数位生物标记是透过穿戴式感测器、行动应用程式和植入式技术等数位装置收集的客观、可量化的生理和行为数据。这些生物标记物可以捕捉运动、认知、言语、睡眠和其他神经功能的变化，从而能够持续监测疾病进展、治疗反应，并早期发现帕金森氏症、阿兹海默症和多发性硬化症等神经系统疾病。透过整合进阶分析和人工智慧，数位生物标记物可以提供个人洞察，支援临床决策，并促进远端患者管理。

神经系统疾病盛行率上升

老年人和高风险族群的神经退化性疾病正日益激发人们对非侵入性追踪工具的兴趣。行动感测器、穿戴式装置和人工智慧平台正在将诊断能力扩展到传统临床环境之外。远端监控和远端医疗的整合正在推动整个医疗保健系统的采用。研究机构和医疗技术创新者正在推动即时神经系统数据收集。这些趋势预计将显着推动神经系统疾病数位生物标记物市场的发展。

缺乏标准化和检验

碎片化的通讯协定和不一致的资料流程限制了跨平台相容性。有限的基准测试限制了多中心试验，并延缓了全球推广。医疗保健提供者面临着将多样化资料流整合到现有系统中的挑战。开发人员必须投资协调框架和强大的检验流程，以克服这些障碍。这些限制预计将限制神经系统疾病数位生物标记物市场的发展。

转向个人化和预防性医疗保健

个人化认知和运动症状追踪正在重塑病人参与。与行动应用程式、云端平台和穿戴式感测器的整合正在加速临床和消费者层面的采用。公共卫生倡议和雇主健康计画正在推动认知和运动监测工具的早期采用。对预防性脑健康管理的需求正在推动自适应生物标记系统的创新。这些趋势预计将显着推动神经系统疾病数位生物标记市场的发展。

开发和实施成本高

资金和技术需求限制了新兴企业的进入。专用硬体、资料基础架构和合规性要求降低了可负担性并减缓了部署速度。临床检验和纵向研究需要大量投资和营运能力。规模较小的公司在获得报销和机构合作方面面临障碍。这些限制预计将阻碍神经系统疾病数位生物标记物市场的发展。

COVID-19的影响：

新冠疫情扰乱了临床试验，并减缓了数位生物标记物技术在神经系统护理领域的部署。远端监控的需求和虚拟诊断的应用加速了人们对基于感测器的神经追踪技术的兴趣。在疫情封锁期间，穿戴式装置和行动平台因监测认知和运动症状而变得流行。混合护理模式和远距神经病学正在扩大疫情后数位生物标记工具的可及性。公共卫生部门对心理韧性和长期神经系统影响的关注，正在推动对可扩展解决方案的投资。这些转变预计将推动神经系统疾病数位生物标记物市场的发展。

穿戴式装置市场预计将成为预测期内最大的市场

由于神经系统疾病盛行率的上升以及对持续真实世界数据收集的需求，预计可穿戴设备领域将在预测期内占据最大的市场份额。智慧型手錶、生物感测器和运动追踪器正在推动临床和消费者的采用。在医院、研究中心和家庭护理环境中，运动功能、睡眠和认知监测的应用日益增加。与人工智慧分析和云端平台的整合正在促进即时决策支援。製造商正在投资于能够应对多种情况的多功能性和用户友好型格式。预计该领域将显着推动神经系统疾病数位生物标记市场的发展。

帕金森氏症领域预计将在预测期内以最高的复合年增长率成长

预计帕金森氏症领域将在预测期内实现最高成长率，推动对精准运动和认知追踪的需求。数位生物标记有助于帕金森氏症的早期诊断、症状进展监测和治疗优化。穿戴式装置、语音分析和步态感测器正在加速临床研究和患者参与。与远端医疗平台和个人化治疗模式的整合正在推动其应用。开发人员正专注于扩充性且有效的工具，以满足帕金森氏症的特定需求。预计该领域将推动神经系统疾病数位生物标记物市场的发展。

比最大的地区

预计亚太地区将在预测期内占据最大的市场份额，这得益于神经系统疾病负担的增加和区域创新。快速的都市化、人口老化以及不断扩展的数位健康基础设施正在推动需求。中国、印度、日本和韩国正在扩大神经復健和认知健康计画。本地生产和具有竞争力的价格正在推动这些项目的采用。政府在精神健康和老年护理方面的支持措施正在推动市场扩张。这些趋势预计将显着推动亚太地区神经系统疾病数位生物标记市场的发展。

复合年增长率最高的地区：

在预测期内，北美预计将见证最高的复合年增长率，这得益于神经系统疾病的日益普及以及对脑健康创新的强劲投资。美国和加拿大正在将数位生物标记整合到临床试验、远端医疗和个人化神经病学平台。学术机构和新兴企业正在推动非侵入性追踪和人工智慧主导分析领域的创新。监管部门对数位健康技术的支持正在加速市场渗透。官民合作关係和报销范围的扩大正在推动整个医疗保健系统的采用。这些发展预计将推动北美神经系统疾病数位生物标记物市场的发展。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章神经系统疾病数位生物标记市场（按类型）

  • 穿戴式装置
    • 智慧型手錶
    • 健身追踪器
    • 生物感测器
  • 行动应用程式
  • 感应器
    • 脑波感测器
    • 心电图感测器
    • 动作感测器
  • 软体平台
    • 数据分析工具
    • 云端基础的平台

第六章神经系统疾病数位生物标记市场（按适应症）

  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 癫痫
  • 其他适应症

7. 神经系统疾病数位生物标记市场（依临床应用）

  • 诊断生物标记
  • 生物标记监测
    • 疾病进展追踪
    • 治疗反应评估
  • 预测性生物标记
    • 风险评估模型
    • 预后指标

8. 全球神经系统疾病数位生物标记市场（按最终用户）

  • 医疗保健提供者
    • 医院
    • 神经科诊所
  • 医疗保健公司
    • 製药公司
    • 生技公司
  • 研究机构
    • 学术机构
    • 临床研究所

9. 全球神经系统疾病数位生物标记市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • NeuraLight
  • MindMaze SA
  • Neuroelectrics
  • Emotiv Inc.
  • NeuroPace, Inc.
  • Kernel
  • Cognifit Inc.
  • Posit Science Corporation
  • OpenBCI
  • Flow Neuroscience
  • BrainCo, Inc.
  • Novela Neurotechnologies
  • BioSensics LLC
  • Aural Analytics, Inc.
  • Quantified Health
Product Code: SMRC31390

According to Stratistics MRC, the Global Digital Biomarkers for Neurological Conditions Market is accounted for $894.9 million in 2025 and is expected to reach $4638.6 million by 2032 growing at a CAGR of 26.5% during the forecast period. Digital biomarkers for neurological conditions are objective, quantifiable physiological and behavioral data collected through digital devices such as wearable sensors, mobile apps, or implantable technologies. These biomarkers capture changes in movement, cognition, speech, sleep, and other neurological functions, enabling continuous monitoring of disease progression, treatment response, and early detection of neurological disorders like Parkinson's, Alzheimer's, and multiple sclerosis. By integrating advanced analytics and artificial intelligence, digital biomarkers provide personalized insights, support clinical decision-making, and facilitate remote patient management, improving outcomes while reducing reliance on traditional, episodic clinical assessments.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

Neurodegenerative conditions across aging and at-risk populations are accelerating interest in non-invasive tracking tools. Mobile sensors, wearables, and AI-powered platforms are expanding diagnostic capabilities beyond traditional clinical settings. Integration with remote monitoring and telemedicine is fostering adoption across healthcare systems. Research institutions and medtech innovators are propelling real-time neurological data capture. These dynamics are expected to significantly boost the digital biomarkers for neurological conditions market.

Restraint:

Lack of standardization and validation

Fragmented protocols and inconsistent data pipelines limit cross-platform compatibility. Limited benchmarking is constraining multi-center trials and slowing global deployment. Healthcare providers face challenges in integrating diverse data streams into existing systems. Developers must invest in harmonization frameworks and robust validation pipelines to overcome these barriers. These limitations are expected to constrain the digital biomarkers for neurological conditions market.

Opportunity:

Shift toward personalized and preventive healthcare

Individualized tracking of cognitive and motor symptoms is reshaping patient engagement. Integration with mobile apps, cloud platforms, and wearable sensors is accelerating uptake in both clinical and consumer settings. Public health initiatives and employer wellness programs are fostering early adoption of cognitive and motor monitoring tools. Demand for proactive brain health management is propelling innovation in adaptive biomarker systems. These trends are expected to significantly boost the digital biomarkers for neurological conditions market.

Threat:

High development and implementation costs

Financial and technical demands restrict entry for emerging players. Specialized hardware, data infrastructure, and compliance requirements are degrading affordability and slowing deployment. Clinical validation and longitudinal studies demand substantial investment and operational capacity. Smaller players face barriers in accessing reimbursement and institutional partnerships. Such constraints are expected to hinder the digital biomarkers for neurological conditions market.

Covid-19 Impact:

The Covid-19 pandemic disrupted clinical trials and delayed deployment of digital biomarker technologies across neurological care pathways. Remote monitoring demand and virtual diagnostics adoption accelerated interest in sensor-based neurological tracking. Wearables and mobile platforms gained traction during lockdowns for cognitive and motor symptom surveillance. Hybrid care models and tele-neurology are expanding access to digital biomarker tools post-pandemic. Public health focus on mental resilience and long-term neurological effects is fostering investment in scalable solutions. These shifts are expected to propel the digital biomarkers for neurological conditions market.

The wearable devices segment is expected to be the largest during the forecast period

The wearable devices segment is expected to account for the largest market share during the forecast period due to rising neurological disorder prevalence and demand for continuous, real-world data capture. Smartwatches, biosensors, and motion trackers are driving clinical and consumer adoption. Hospitals, research centres, and home-care settings are expanding use for motor function, sleep, and cognitive monitoring. Integration with AI analytics and cloud platforms is fostering real-time decision support. Manufacturers are investing in multi-condition versatility and user-friendly formats. This segment is expected to significantly boost the digital biomarkers for neurological conditions market.

The Parkinson's disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Parkinson's disease segment is predicted to witness the highest growth rate drives demand for precise motor and cognitive tracking. Digital biomarkers are enabling early diagnosis, symptom progression monitoring, and therapy optimization in Parkinson's care. Wearables, voice analytics, and gait sensors are accelerating clinical research and patient engagement. Integration with remote care platforms and personalized treatment models is fostering adoption. Developers are focusing on scalable, validated tools tailored to Parkinson's-specific needs. This segment is expected to propel the digital biomarkers for neurological conditions market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by rising neurological disease burden and regional innovation. Rapid urbanization, aging demographics, and expanding digital health infrastructure are accelerating demand. China, India, Japan, and South Korea are scaling neurorehabilitation and cognitive wellness programs. Local manufacturing and competitive pricing are fostering widespread adoption. Government-backed initiatives in mental health and aging care are propelling market expansion. These dynamics are expected to significantly boost the Asia Pacific digital biomarkers for neurological conditions market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR propelled by neurological disorder prevalence and strong investment in brain health innovation. United States and Canada are integrating digital biomarkers into clinical trials, remote care, and personalized neurology platforms. Academic institutions and startups are fostering innovation in non-invasive tracking and AI-driven analytics. Regulatory support for digital health technologies is accelerating market penetration. Public-private partnerships and reimbursement expansion are driving adoption across healthcare systems. These developments are expected to propel the North America digital biomarkers for neurological conditions market.

Key players in the market

Some of the key players in Digital Biomarkers for Neurological Conditions Market include NeuraLight, MindMaze SA, Neuroelectrics, Emotiv Inc., NeuroPace, Inc., Kernel, Cognifit Inc., Posit Science Corporation, OpenBCI, Flow Neuroscience, BrainCo, Inc., Novela Neurotechnologies, BioSensics LLC, Aural Analytics, Inc. and Quantified Health.

Key Developments:

In September 2025, NeuraLight partnered with the CHDI Foundation to develop precision eye movement biomarkers for Huntington's disease. This collaboration aims to create sensitive, trial-ready tools to support clinical trials and therapeutic development for Huntington's disease.

In July 2025, NeuroX acquired the assets and operations of MindMaze, a recognized leader in digital neurotherapeutics. This acquisition aimed to enhance NeuroX's capabilities in providing disease-modifying motor and cognitive treatments for neurological diseases and brain disorders.

Types Covered:

  • Wearable Devices
  • Mobile Applications
  • Sensors
  • Software Platforms
  • Data Analytics Tools
  • Cloud-Based Platforms

Indications Covered:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Other Indication

Clinical Applications Covered:

  • Diagnostic Biomarkers
  • Monitoring Biomarkers
  • Disease Progression Tracking
  • Treatment Response Assessment
  • Predictive Biomarkers
  • Risk Assessment Models
  • Prognostic Indicators

End Users Covered:

  • Healthcare Providers
  • Healthcare Companies
  • Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Biomarkers for Neurological Conditions Market, By Type

  • 5.1 Introduction
  • 5.2 Wearable Devices
    • 5.2.1 Smartwatches
    • 5.2.2 Fitness Trackers
    • 5.2.3 Biosensors
  • 5.3 Mobile Applications
  • 5.4 Sensors
    • 5.3.1 EEG Sensors
    • 5.3.2 ECG Sensors
    • 5.3.3 Motion Sensors
  • 5.5 Software Platforms
    • 5.5.1 Data Analytics Tools
    • 5.5.2 Cloud-Based Platforms

6 Global Digital Biomarkers for Neurological Conditions Market, By Indication

  • 6.1 Introduction
  • 6.2 Alzheimer's Disease
  • 6.3 Parkinson's Disease
  • 6.4 Multiple Sclerosis
  • 6.5 Epilepsy
  • 6.6 Other Indication

7 Global Digital Biomarkers for Neurological Conditions Market, By Clinical Application

  • 7.1 Introduction
  • 7.2 Diagnostic Biomarkers
  • 7.3 Monitoring Biomarkers
    • 7.3.1 Disease Progression Tracking
    • 7.3.2 Treatment Response Assessment
  • 7.4 Predictive Biomarkers
    • 7.4.1 Risk Assessment Models
    • 7.4.2 Prognostic Indicators

8 Global Digital Biomarkers for Neurological Conditions Market, By End User

  • 8.1 Introduction
  • 8.2 Healthcare Providers
    • 8.2.1 Hospitals
    • 8.2.2 Neurology Clinics
  • 8.3 Healthcare Companies
    • 8.3.1 Pharmaceutical Companies
    • 8.3.2 Biotech Firms
  • 8.4 Research Organizations
    • 8.4.1 Academic Institutions
    • 8.4.2 Clinical Research Organizations

9 Global Digital Biomarkers for Neurological Conditions Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 NeuraLight
  • 11.2 MindMaze SA
  • 11.3 Neuroelectrics
  • 11.4 Emotiv Inc.
  • 11.5 NeuroPace, Inc.
  • 11.6 Kernel
  • 11.7 Cognifit Inc.
  • 11.8 Posit Science Corporation
  • 11.9 OpenBCI
  • 11.10 Flow Neuroscience
  • 11.11 BrainCo, Inc.
  • 11.12 Novela Neurotechnologies
  • 11.13 BioSensics LLC
  • 11.14 Aural Analytics, Inc.
  • 11.15 Quantified Health

List of Tables

  • Table 1 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Wearable Devices (2024-2032) ($MN)
  • Table 4 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Smartwatches (2024-2032) ($MN)
  • Table 5 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Fitness Trackers (2024-2032) ($MN)
  • Table 6 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Biosensors (2024-2032) ($MN)
  • Table 7 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Mobile Applications (2024-2032) ($MN)
  • Table 8 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Sensors (2024-2032) ($MN)
  • Table 9 Global Digital Biomarkers for Neurological Conditions Market Outlook, By EEG Sensors (2024-2032) ($MN)
  • Table 10 Global Digital Biomarkers for Neurological Conditions Market Outlook, By ECG Sensors (2024-2032) ($MN)
  • Table 11 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Motion Sensors (2024-2032) ($MN)
  • Table 12 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Software Platforms (2024-2032) ($MN)
  • Table 13 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Data Analytics Tools (2024-2032) ($MN)
  • Table 14 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Cloud-Based Platforms (2024-2032) ($MN)
  • Table 15 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Indication (2024-2032) ($MN)
  • Table 16 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 17 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 18 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 19 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 20 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Other Indication (2024-2032) ($MN)
  • Table 21 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Clinical Application (2024-2032) ($MN)
  • Table 22 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Diagnostic Biomarkers (2024-2032) ($MN)
  • Table 23 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Monitoring Biomarkers (2024-2032) ($MN)
  • Table 24 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Disease Progression Tracking (2024-2032) ($MN)
  • Table 25 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Treatment Response Assessment (2024-2032) ($MN)
  • Table 26 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Predictive Biomarkers (2024-2032) ($MN)
  • Table 27 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Risk Assessment Models (2024-2032) ($MN)
  • Table 28 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Prognostic Indicators (2024-2032) ($MN)
  • Table 29 Global Digital Biomarkers for Neurological Conditions Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 31 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Neurology Clinics (2024-2032) ($MN)
  • Table 33 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Healthcare Companies (2024-2032) ($MN)
  • Table 34 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 35 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Biotech Firms (2024-2032) ($MN)
  • Table 36 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 37 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Academic Institutions (2024-2032) ($MN)
  • Table 38 Global Digital Biomarkers for Neurological Conditions Market Outlook, By Clinical Research Organizations (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.